A CBD/THC Combination Did Not Significantly Improve Chemotherapy-Induced Nerve Damage in a Rigorous Trial
In a 12-week randomized double-blind trial, a CBD/THC combination did not significantly improve the primary outcome of sensory neuropathy symptoms in cancer patients with chemotherapy-induced peripheral neuropathy, though some secondary measures trended toward improvement.
Quick Facts
What This Study Found
The active group receiving CBD (125.3–135.9 mg) combined with THC (6.0–10.8 mg) in gelcaps did not show statistically significant improvement on the primary outcome (QLQ-CIPN20 sensory subscale) compared to placebo over 12 weeks, though some secondary endpoints suggested potential trends.
Key Numbers
12-week double-blind RCT. Active: CBD 125.3–135.9 mg + THC 6.0–10.8 mg in gelcaps. Cancer types: breast, colorectal, endometrial, ovarian. CIPN grade 2–3. Primary outcome (CIPN20 sensory): not significantly different from placebo.
How They Did This
12-week randomized, double-blind, placebo-controlled trial in patients with nonmetastatic breast, colorectal, endometrial, or ovarian cancer experiencing grade 2–3 CIPN from taxane- or platinum-based chemotherapy. Active arm received CBD (125.3–135.9 mg) + THC (6.0–10.8 mg) in gelcaps. Primary outcome: QLQ-CIPN20 sensory subscale.
Why This Research Matters
This is one of the first rigorous RCTs testing cannabinoids for CIPN. While the negative primary result is disappointing, it provides crucial evidence to temper enthusiasm from smaller, uncontrolled studies and helps define where future research should focus.
The Bigger Picture
In an era of cannabis hype for many conditions, negative results from rigorous trials are essential for evidence-based medicine. This doesn't mean cannabinoids can't help CIPN — it means this specific formulation and dose may not be sufficient, and future trials should explore different approaches.
What This Study Doesn't Tell Us
Specific formulation and dose may not represent optimal cannabinoid therapy for CIPN. Duration (12 weeks) may be insufficient. Grade 2–3 CIPN may be harder to treat than earlier stages. Sample characteristics not fully described in abstract.
Questions This Raises
- ?Would higher doses or different THC:CBD ratios be more effective?
- ?Is topical rather than oral administration better for peripheral neuropathy?
- ?Should future trials target earlier-stage CIPN?
- ?Are there subgroups who benefited?
Trust & Context
- Key Stat:
- Evidence Grade:
- Gold-standard randomized, double-blind, placebo-controlled trial providing high-quality evidence for this specific formulation and indication.
- Study Age:
- Published 2025.
- Original Title:
- Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.
- Published In:
- Frontiers in oncology, 15, 1590168 (2025)
- Authors:
- Weiss, Marisa, Giaddui, Muath, Kjelstrom, Stephanie, Gary, Joseph, Ward, Sara Jane, Burrell, Jessica, Diguilio, Katherine, Bidas, Gabrielle, Erebor, Ebuwa, Meske, Sam, Saeed, Lisa, Windawi, Sarah, Aliano Ruiz, Katherine, Ghaneie, Arezoo, Hibbs, Julianne, Marks, John, Holtz, David, Ali, Zonera, Shevade, Aarthi, Sabol, Jennifer, Ciocca, Robin, Zeger, Eric, Gilman, Paul, Larson, Sharon, Shimamoto, Shoichi, Martinez, Diana
- Database ID:
- RTHC-07936
Evidence Hierarchy
Frequently Asked Questions
Does this mean cannabis doesn't help with chemo nerve damage?
It means this specific CBD/THC formulation at this dose didn't beat placebo for sensory neuropathy over 12 weeks. Different doses, routes (topical), or formulations might perform differently. More research is needed.
Why did earlier studies show cannabis helps neuropathy?
Earlier studies were often smaller, uncontrolled, or used different outcomes. Rigorous double-blind trials sometimes don't replicate initial positive results because they control for placebo effects, which can be substantial in pain research.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- why-does-weed-make-music-sound-better
- why-does-weed-give-cotton-mouth-salivary
- cannabis-and-carpal-tunnel-nerve-pain
Cite This Study
https://rethinkthc.com/research/RTHC-07936APA
Weiss, Marisa; Giaddui, Muath; Kjelstrom, Stephanie; Gary, Joseph; Ward, Sara Jane; Burrell, Jessica; Diguilio, Katherine; Bidas, Gabrielle; Erebor, Ebuwa; Meske, Sam; Saeed, Lisa; Windawi, Sarah; Aliano Ruiz, Katherine; Ghaneie, Arezoo; Hibbs, Julianne; Marks, John; Holtz, David; Ali, Zonera; Shevade, Aarthi; Sabol, Jennifer; Ciocca, Robin; Zeger, Eric; Gilman, Paul; Larson, Sharon; Shimamoto, Shoichi; Martinez, Diana. (2025). Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.. Frontiers in oncology, 15, 1590168. https://doi.org/10.3389/fonc.2025.1590168
MLA
Weiss, Marisa, et al. "Combination CBD/THC in the management of chemotherapy-induced peripheral neuropathy: a randomized double blind controlled trial.." Frontiers in oncology, 2025. https://doi.org/10.3389/fonc.2025.1590168
RethinkTHC
RethinkTHC Research Database. "Combination CBD/THC in the management of chemotherapy-induce..." RTHC-07936. Retrieved from https://rethinkthc.com/research/weiss-2025-combination-cbdthc-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.